| 蒋雨卉,石 兵,聂 刚,杨晓玲,黄 颖.血清miR-92a在胰腺癌诊断及预后评估中的临床意义研究[J].,2017,17(31):6111-6115 |
| 血清miR-92a在胰腺癌诊断及预后评估中的临床意义研究 |
| Clinical Significance of Serum miR-92a in Diagnosis and Prognosis Evaluation of Pancreatic Cancer |
| 投稿时间：2017-06-06 修订日期：2017-06-30 |
| DOI：10.13241/j.cnki.pmb.2017.31.026 |
| 中文关键词: 胰腺癌 miR-92a 糖蛋白抗原19-9 分子标志物 诊断 预后 |
| 英文关键词: Pancreatic cancer miR-92a Carbohydrate antigen 19-9 Molecular marker Diagnosis Prognosis |
| 基金项目:重庆市卫生计生委2014年医学科研面上项目（20142066） |
|
| 摘要点击次数: 331 |
| 全文下载次数: 188 |
| 中文摘要: |
| 摘要 目的：探讨血清miR-92a在胰腺癌诊断和预后分析中的价值，为胰腺癌早诊断以及预后评估提供潜在的分子标志物。方法：回顾性分析我院及重庆医科大学附属第一、第二医院2014年8月~2016年12月收治的30例胰腺癌未转移患者、30例胰腺癌转移患者和30例慢性胰腺炎患者的临床资料，另选择同期在我院进行健康体检的30例健康人作为健康组。收集血清，应用定量PCR法检测各组血清miR-92a的表达水平，利用化学发光法检测各组血清中的糖蛋白抗原19-9（CA-19-9）含量。以ROC分析比较血清miR-92a与CA 19-9在胰腺癌诊断中的特异度、敏感性。结果：胰腺癌未转移组患者和胰腺癌转移组患者血清中miR-92a水平显著高于健康组和慢性胰腺炎组（P＜0.05），胰腺癌转移组患者血清中miR-92a水平显著高于胰腺癌未转移组患者（P＜0.05）。胰腺癌未转移组患者和胰腺癌转移组患者血清中CA19-9水平显著高于健康组和慢性胰腺炎组（P＜0.05）。miR-92a诊断胰腺癌的敏感度高于CA19-9和miR-92a+CA 19-9，而miR-92a+CA 19-9诊断胰腺癌的特异度显著高于miR-92a和CA19-9（P<0.05），且有较高的胰腺癌转移预测应用价值。结论：血清miR-92a联合CA 19-9检测能够诊断胰腺癌，具有良好的敏感度和特异度，miR-92a还具有较好的胰腺癌转移预测价值，可作为胰腺癌早期无创筛查方法加以应用。 |
| 英文摘要: |
| ABSTRACT Objective: To investigate the value of serum miR-92a in the diagnosis and prognosis analysis of pancreatic cancer,and to provide potential molecular markers for the early diagnosis and prognosis evaluation of pancreatic cancer. Methods: The clinical data of 30 cases of pancreatic cancer without metastasis, 30 cases of pancreatic cancer with metastasis, 30 cases of chronic pancreatitis, who werte treated in University Town Hospital of Chongqing Medical University, the First Affiliated Hospital of Chongqing Medical Univer- sity and the Second Affiliated Hospital of Chongqing Medical University from August 2014 to December 2016, were retrospectively ana- lyzed. In addition, 30 healthy people, who underwent physical examination in the hospital during the same period, were chosen as healthy group.Serum samples were collected and the expression level of serum miR-92a was detected by quantitative PCR method. The content of carbohydrate antigen 19-9 (CA 19-9) from serum in each group was detected by chemiluminescence method.ROC analysis was used to compare the specificity and sensitivity of serum miR-92a and CA 19-9 in the diagnosis of pancreatic cancer. Results: The levels of serum miR-92a in pancreatic cancer patients without metastasis group and with metastasis group were significantly higher than those in healthy group and chronic pancreatitis group (P<0.05). The level of serum miR-92a in pancreatic cancer patients with metastasis group was sig- nificantly higher than that in pancreatic cancer patients without metastasis group (P<0.05). The serum levels of CA19-9 in pancreatic can- cer patients without metastasis group and with metastasis group were significantly higher than those in healthy group and chronic pancre- atitis group (P<0.05). The sensitivity of miR-92a in diagnosing pancreatic cancer was higher than CA19-9 and miR-92a+CA 19-9, while the specificity of miR-92a+CA 19-9 in diagnosing pancreatic cancer was significantly higher than miR-92a and CA19-9 (P<0.05), which had higher predictive application value for metastasis of pancreatic cancer. Conclusion: Serum miR-92a combined with CA 19-9 can di- agnose pancreatic cancer,with good sensitivity and specificity. The miR-92a also has good predictive value for metastasis of pancreatic cancer, which can be used as an early noninvasive screening method for pancreatic cancer. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
